INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 539.6000.11	FOR FURTHER ACTION	See item 4 below	
International application No. PCT/US2004/042376	International filing date (day/month/year) 17 December 2004 (17.12.2004)	Priority date (day/month/year) 17 December 2003 (17.12.2003)	
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237			
Applicant MEDTRONIC PHYSIO-CONTROI	CORP.	-	

1.	This international pruliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis. I(a).					
2.	This REPORT consists of a total of 6 sheets, including this cover sheet.					
	In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.					
3.	This report contains indications	relating to the following items:				
	Box No. I	Basis of the report				
	Box No. II	Priority				
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
	Box No. IV	Lack of unity of invention				
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
	Box No. VI	Certain documents cited				
	Box No. VII	Certain defects in the international application				
	Box No. VIII	Certain observations on the international application				
4.	The International Bureau will c not, except where the applicant date (Rule 44bis .2).	ommunicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but makes an express request under Article 23(2), before the expiration of 30 months from the priority				

	Date of issuance of this peport 20 June 2006 (20.06.2006)
The International Bureau of WIPO	Authorized officer
34, chemin des Colombettes 1211 Geneva 20, Switzerland	Agnes Wittmann-Regis
Facsimile No. +41 22 740 14 35	Telephone No. +41 22 338 89 70
Porm DCT/ID /272 (Iunum) 2004)	<u> </u>

REC'D 22 MAR SOOK

INTERNATIONAL SEARCHING AUTHORITY

		-	•	а	LILILI	6989
i	WIP	Ö	_	-	········	PO

_	_	_
\Box	\sim	7

see form PCT/ISA/220

To:

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)

Date of mailing		•
(day/month/year)	see form PCT/ISA/210 (second sheet)	

17.12.2003

Priority date (daymonth/year)

Applicant's or agent's file reference see form PCT/ISA/220 u International application No.

FOR FURTHER ACTION See paragraph 2 below

PCT/US2004/042376 17.12.2004 International Patent Classification (IPC) or both national classification and IPC

A61N1/39, A61N1/18, A61N1/08

MEDTRONIC PHYSIO-CONTROL CORP.

- This opinion contains indications relating to the following items:
 - Box No. i Basis of the opinion
 - ☐ Box No. II Priority
 - ☐ Box No. III
 - Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

international filing date (daytmonth/year)

- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- □ Box No. VII Certain defects in the international application.
- Box No. VIII Certain observations on the international application
- **FURTHER ACTION**

if a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"), However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1 bis(b) that written opinions of this international Searching Authority will not be so considered

if this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of malling of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

Authorized Officer Chopinaud, M.

Telephone No. +49 89 2399-7365



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2004/042376

Box I					
	No. I Basis of the opinion				
With the la	regard to the language, this opinion has been established on the basis of the international application in nguage in which it was filed, unless otherwise indicated under this item.				
	his opinion has been established on the basis of a translation from the original language into the following inguage , which is the language of a translation furnished for the purposes of international search inder Rules 12.9 and 23.7(b)).				
With a	egard to any nucleotide and/or amino acid sequence disclosed in the international application and sary to the claimed invention, this opinion has been established on the basis of:				
a. type of material:					
	a sequence listing				
	table(s) related to the sequence listing				
b. for	nat of material:				
	in written format				
	in computer readable form				
c. time	of filing/furnishing:				
	contained in the international application as filed.				
	filed together with the international application in computer readable form.				
	furnished subsequently to this Authority for the purposes of search.				
C	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto to been filed or furnished, the required statements that the information in the subsequent or additional ples is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.				
	a. type				

Additional comments:

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims

No: Claims 1-31

Inventive step (IS) Yes: Claims

No: Claims 1-31

Industrial applicability (IA) Yes: Claims 1-31

No: Claims

2. Citations and explanations

see separate sheet

Re Item V.

1 Reference is made to the following documents:

D1: US 5 105 821 A (REYES ET AL) 21 April 1992 (1992-04-21)

D2: EP 1 250 944 A (GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES,

INC) 23 October 2002 (2002-10-23)

D3: US 3 865 101 A (SAPER ET AL) 11 February 1975 (1975-02-11)

D4: WO 01/66182 A (CARDIAC SCIENCE, INC) 13 September 2001 (2001-09-13)

Although claims 1, 22 and 28 have been drafted as separate independent claims, they appear to relate effectively to the same subject-matter and to differ from each other only with regard to the definition of the subject-matter for which protection is sought and in respect of the terminology used for the features of that subject-matter. The aforementioned claims therefore lack conciseness and as such do not meet the requirements of Article 6 PCT. For this reason, only claim 1 will be studied in details.

3 INDEPENDENT CLAIM 1

The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of **claim 1 is not new** in the sense of Article 33(2) PCT.

Document D1 discloses (the references in parentheses applying to this document)

a modular external defibrillator system, comprising:

- a base (element 14, figure 1) containing a defibrillator module to deliver a defibrillation shock to a patient;
- a patient parameter monitoring pod (monitor 14, figure 1) connectable to a patient via patient lead cables to collect patient data, the patient data including at least one patient vital sign; and
- a **power supply sharing link** (link 40, figure 1) between the base and the pod, the pod receiving power from the base via the power sharing link, the pod being operable to collect patient data without receiving power from the base (column 5, line 4-34).

4 DEPENDENT CLAIMS 2-21

Dependent claims 2-21 contain either features known per se from the prior art or being simple constructional features. Thus they would only satisfy Art. 33(2),(3) PCT when referring to a patentable independent claim.

In order to facilitate the examination of the conformity of the amended application with the requirements of Art. 34(2)(b) PCT, the applicant is requested to clearly identify the amendments carried out, no matter whether they concern amendments by addition, replacement or deletion, and to indicate the passages of the application as filed on which these amendments are based (see also Rule 66.8(a) PCT).

If the applicant regards it as appropriate these indications could be submitted in handwritten form on a copy of the relevant parts of the application as filed.